{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:26:28Z","timestamp":1760646388157},"reference-count":39,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T00:00:00Z","timestamp":1443571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Mundipharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>In April 2014, a tamper\u2010resistant controlled\u2010release oxycodone formulation was released in Australia. We aimed to determine whether there are latent classes of people who tamper with pharmaceutical opioids based on frequency of opioid and illicit drug use, the demographic and clinical profiles of these groups, and if there were changes in use and harms following the introduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective cohort of 606 people who regularly tamper with pharmaceutical opioids was interviewed January to March 2014 (Wave 1) and May to August 2014 (Wave 2). Latent class analysis identified groups based on non\u2010prescribed opioid, illicit drug and prescribed opioid substitution therapy (OST) use at Wave 1. Regression models examined whether group membership predicted use and harms at Wave 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four groups were identified: <jats:italic>frequent OST group<\/jats:italic> (39%), <jats:italic>mixed OST<\/jats:italic>\/<jats:italic>heroin group<\/jats:italic> (7%), <jats:italic>infrequent pharmaceutical opioid and heroin group<\/jats:italic> (44%) and <jats:italic>frequent oxycodone group<\/jats:italic> (25%). Compared with the <jats:italic>frequent OST group<\/jats:italic>, the <jats:italic>infrequent pharmaceutical opioid<\/jats:italic>\/<jats:italic>heroin group<\/jats:italic> was more likely to report non\u2010everyday pain and risky alcohol use, and the <jats:italic>frequent oxycodone group<\/jats:italic> had higher odds of homelessness. At Wave 2, oxycodone use decreased across groups (odds ratios (OR)\u2009\u2264\u20090.18, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, particularly for the <jats:italic>frequent oxycodone group<\/jats:italic>: OR\u2009\u2264\u20090.05, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with reductions in days of use (<jats:italic>g<\/jats:italic>\u2009\u2265\u20090.35, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.050). Non\u2010prescribed pharmaceutical opioid use, illicit drug use and harms remained stable or decreased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite heterogeneity among people who tamper with pharmaceutical opioids, the tamper\u2010resistant formulation was followed by reductions in oxycodone tampering among high\u2010frequency and low\u2010frequency users. There was no evidence of increased use of other opioids or illicit drugs. Copyright \u00a9 2015 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3883","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T08:23:38Z","timestamp":1443601418000},"page":"1321-1333","source":"Crossref","is-referenced-by-count":4,"title":["A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper\u2010resistant formulation of controlled\u2010release oxycodone"],"prefix":"10.1002","volume":"24","author":[{"given":"Amy","family":"Peacock","sequence":"first","affiliation":[{"name":"School of Medicine (Psychology) University of Tasmania  Hobart Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre University of New South Wales  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briony","family":"Larance","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre University of New South Wales  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cama","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre University of New South Wales  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[{"name":"Discipline of Addiction Medicine, Faculty of Medicine Sydney University  Sydney New South Wales Australia"},{"name":"The Langton Centre South East Sydney Local Health District (SESLHD) Drug and Alcohol Services  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ali","sequence":"additional","affiliation":[{"name":"University of Adelaide  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimondo","family":"Bruno","sequence":"additional","affiliation":[{"name":"School of Medicine (Psychology) University of Tasmania  Hobart Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.009"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12446"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00283.x"},{"key":"e_1_2_9_5_1","volume-title":"Australian Drug Trends 2013: Findings from the Illicit Drug Reporting System (IDRS)","author":"Stafford J","year":"2014"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.02.022"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.08.008"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113493364"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.02.018"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2013.04.011"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.02.038"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.05.023"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1204141"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.10.004"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2011.00302.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027244"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2014.962661"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.08.029"},{"key":"e_1_2_9_19_1","unstructured":"Australian Bureau of Statistics.3218.0 Regional population growth Australia 2013\u20132014 2015.http:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/mf\/3218.0\/"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12066"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12746"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12279"},{"key":"e_1_2_9_23_1","volume-title":"Composite International Diagnostic Interview Vol Version 3.0","author":"World Health Organisation","year":"2001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1995.9056072.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb02953.x"},{"key":"e_1_2_9_26_1","article-title":"The alcohol use disorders identification test","volume":"2","author":"Babor TF","year":"2001","journal-title":"Guide Use Prim Care"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.08.016"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ecolsys.28.1.341"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.09.014"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/88.3.767"},{"key":"e_1_2_9_31_1","volume-title":"IBM spss Statistics for Windows [Computer Program]","year":"2012"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3102\/10769986006002107"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12192"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2004.04049.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2012.01327.x"},{"issue":"3","key":"e_1_2_9_36_1","first-page":"S67","article-title":"American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non\u2010cancer pain: part 2\u2014guidance","volume":"15","author":"Manchikanti L","year":"2012","journal-title":"Pain Physician"},{"key":"e_1_2_9_37_1","unstructured":"LionbergerR.Future of generic drug development. Development and regulation of abuse\u2010deterrent opioid medications\u2014public meeting;2014; Silver Spring MD."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-6-205"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/J354v20n02_03"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00028-3"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3883","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:57:43Z","timestamp":1696366663000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,30]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/pds.3883"],"URL":"https:\/\/doi.org\/10.1002\/pds.3883","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,30]]}}}